Jordan E Shields
Overview
Explore the profile of Jordan E Shields including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zimowski K, Petrillo T, Ho M, Wechsler J, Shields J, Denning G, et al.
J Thromb Haemost
. 2021 Mar;
19(7):1653-1665.
PMID: 33773040
Background: Elucidating the molecular pathogenesis underlying East Texas bleeding disorder (ET) led to the discovery of alternatively spliced F5 transcripts harboring large deletions within exon 13. These alternatively spliced transcripts...
2.
Lam P, Padula S, Hoang T, Poth J, Liu L, Liang C, et al.
Hum Genomics
. 2019 Feb;
13(1):10.
PMID: 30770771
Background: Despite a number of different transgenes that can mediate DNA deletion in the developing lens, each has unique features that can make a given transgenic line more or less...
3.
Doering C, Denning G, Shields J, Fine E, Parker E, Srivastava A, et al.
Hum Gene Ther
. 2018 Aug;
29(10):1183-1201.
PMID: 30160169
Genetically modified, autologous hematopoietic stem and progenitor cells (HSPCs) represent a new class of genetic medicine. Following this therapeutic paradigm, we are developing a product candidate, designated CD68-ET3-LV CD34, for...
4.
Tran R, Myers D, Denning G, Shields J, Lytle A, Alrowais H, et al.
Mol Ther
. 2017 Aug;
25(10):2372-2382.
PMID: 28780274
Ex vivo gene therapy using lentiviral vectors (LVs) is a proven approach to treat and potentially cure many hematologic disorders and malignancies but remains stymied by cumbersome, cost-prohibitive, and scale-limited...
5.
Brown H, Wright J, Zhou S, Lytle A, Shields J, Spencer H, et al.
Mol Ther Methods Clin Dev
. 2015 May;
1:14036.
PMID: 26015976
Clinical data support the feasibility and safety of adeno-associated viral (AAV) vectors in gene therapy applications. Despite several clinical trials of AAV-based gene transfer for hemophilia B, a unique set...
6.
Dasgupta A, Shields J, Spencer H
Hum Gene Ther
. 2012 Mar;
23(7):711-21.
PMID: 22397715
Multimodal therapy approaches, such as combining chemotherapy agents with cellular immunotherapy, suffers from potential drug-mediated toxicity to immune effector cells. Overcoming such toxic effects of anticancer cellular products is a...